Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: A meta-analysis

Annals of Medicine

Volumn 42, Issue 4, 2010, Pages 305-315

  Zhang, Chun Yu ^a   Sun, Ai Jun ^a   Zhang, Shu Ning ^a   Wu, Chao Neng ^a   Fu, Ming Qiang ^a   Xia, Guang ^a   Wang, Ke Qiang ^a   Zou, Yun Zeng ^a   Ge, Jun Bo ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Cardiovascular events; Intensive glucose control; Meta analysis; Randomized controlled trialstype 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLICLAZIDE; HEMOGLOBIN A1C; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; METFORMIN; PIOGLITAZONE;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE DURATION; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT GAIN;

AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 77952185218     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853891003796752     Document Type: Article

References (32)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes\Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053
2. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus\A scientifi c statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114-126 (Pubitemid 46058619) (Pubitemid 46058619)
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl Med. 1998;339:229-234
4. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421-431
5. Turner RC, Holman RR, Stratton IM, Cull CA, Matthews DR, Manley SE, et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865
6. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572
7. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-U62.
8. Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP, et al. Cardiovascular events and correlates in the Veterans Affairs diabetes feasibility trial\Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes. Arch Intern Med. 1997;157:181-188
9. Turner RC, Holman RR, Cull CA, Stratton IM, Matthews DR, Frighi V, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853
10. Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289
11. Wilcox R, Kupfer S, Erdmann E, PROactive Study investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J. 2008;155:712-717
12. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589
13. Nathan DM, Cleary PA, Backlund JYC, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653
14. Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinop-oulos SS, et al. Cardiovascular outcomes in trials of oral diabetes medications\a systematic review. Arch Intern Med. 2008;168:2070-2080
15. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus\A meta-analysis of randomized trials. JAMA. 2007;298:1180-1188
16. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone\A meta-analysis. JAMA. 2007;298:1189-1195
17. Shamoon H, Duffy H, Fleischer N, Engel S, Saenger P, Strelzyn M, et al. The effect of intensive treatment of diabetes on the development and progreeion of long-term comli-cations in insulin-dependent diabetes-mellitus. N Engl J Med. 1993;329:977-986
18. Ma J, Yang W, Fang N, Zhu W, Wei M. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis. Nutr Metab Cardiovasc Dis. 2009;19:596-603.
19. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P; QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med. 2005;22:399-405.
20. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, met-formin, or glyburide monotherapy. N Engl J Med. 2006;355: 2427-2443
21. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mel-litus. Drug Saf. 2007;30:1127-1142
22. Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia. 1999; 42:406-412 (Pubitemid 29148398) (Pubitemid 29148398)
23. Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, et al. Role of insulin secretion and sensi-tivitv in the evolution of type 2 diabetes in the diabetes prevention program\Effects of lifestyle intervention and metformin. Diabetes. 2005;54:2404-2414
24. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JK, et al. Three-year effi cacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361: 1736-1747
25. Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2009;19: 604-612
26. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Effi cacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-125
27. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696
28. Gerstein HC, Yusuf S, Mann JFE, Hoogwerf B, Zinman B, Held C, et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259
29. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393 (Pubitemid 36159355) (Pubitemid 36159355)
30. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-591
31. Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized trials. Lancet. 2009;373:1765-1772
32. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. systematic review: glucose controle and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009;151:394-403.